Stay updated with breaking news from Pediatrics Severe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.
Company data found the Pfizer vaccine was 90.7% effective against symptomatic disease in children ages 5 to 11 and the FDA said the benefits in giving the vaccine to children outweighed the risks.